Step Therapy with Zytiga & Xtandi – Two Equal Drugs Make Our Insurance Companies Our Doctors!

Recently men with advanced prostate cancer have found that their insurance companies have been dictating what drugs they can get instead of their doctor making the best decision for them. At Malecare we have seen that when a man with metastatic castrate resistant prostate cancer (mCRPC) has finished taking chemotherapy they have been steered by [...]

We Need to Improve Access to Oral Chemotherapy By Changing Insurance Co-Pays and Out-Of-Pocket Expenses

Cancer chemotherapy agents historically have been administered intravenously or by an injection. In recent times there have been a number of emerging oral chemotherapy. Most of us strongly prefer the oral drugs as they are a convenient and noninvasive alternative to intravenous and injected therapies. Additionally, many of the intravenously delivered chemotherapy drugs target and [...]

A Hallmark Moment For Private Medical Insurers – The Impact of the Affordable Care Act

We have just reached a red letter moment in the area of medical insurance. The provision of the Affordable Care Act that requires medical insurers to spend 80% of the consumers’ premium dollars they collect—85% for large group insurers—on actual medical care rather than overhead, marketing expenses and profit just kicked in to effect. This [...]

Go to Top